A Comparison Study With Alendronate and Raloxifene in Postmenopausal Women With Osteoporosis (0217-189)

Condition: Osteoporosis, PostmenopausalInterventions: Drug: MK0217, /Duration of Treatment : 12 Months; Drug: Comparator : raloxifene hydrochloride /Duration of Treatment : 12 MonthsSponsor: Merck Sharp & Dohme Corp.Completed - verified November 2014

http://clinicaltrials.gov/ct2/show/NCT00389740?lup_s=11%2F11%2F2014&lup_d=30

Source: ClinicalTrials.gov - October 18, 2006 Category: Research Source Type: clinical trials